Supernus Pharmaceuticals Inc (NASDAQ:SUPN) VP Victor Vaughn sold 55,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $40.11, for a total transaction of $2,206,050.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) opened at $41.50 on Friday. The company has a market cap of $2,037.67, a P/E ratio of 39.15 and a beta of 1.18. Supernus Pharmaceuticals Inc has a fifty-two week low of $23.10 and a fifty-two week high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.27 by $0.02. The business had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. Supernus Pharmaceuticals’s quarterly revenue was up 41.5% on a year-over-year basis. equities research analysts forecast that Supernus Pharmaceuticals Inc will post 1.07 EPS for the current fiscal year.

Several brokerages have commented on SUPN. Stifel Nicolaus cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 target price for the company. in a report on Tuesday, September 19th. They noted that the move was a valuation call. Janney Montgomery Scott reiterated a “hold” rating and issued a $47.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Cowen reiterated a “buy” rating and issued a $50.00 target price on shares of Supernus Pharmaceuticals in a report on Thursday, September 21st. Jefferies Group reiterated a “buy” rating and issued a $51.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Finally, Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $47.00 target price for the company in a report on Wednesday, November 8th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $50.00.

Several hedge funds have recently bought and sold shares of SUPN. Schwab Charles Investment Management Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 4.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 203,197 shares of the specialty pharmaceutical company’s stock worth $8,758,000 after purchasing an additional 7,918 shares during the period. Legal & General Group Plc boosted its holdings in shares of Supernus Pharmaceuticals by 9.5% during the second quarter. Legal & General Group Plc now owns 90,087 shares of the specialty pharmaceutical company’s stock worth $3,881,000 after purchasing an additional 7,815 shares during the period. State Board of Administration of Florida Retirement System boosted its holdings in shares of Supernus Pharmaceuticals by 2.9% during the second quarter. State Board of Administration of Florida Retirement System now owns 23,677 shares of the specialty pharmaceutical company’s stock worth $1,020,000 after purchasing an additional 671 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 17.7% during the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after purchasing an additional 517 shares during the period. Finally, Prudential Financial Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 94.1% during the second quarter. Prudential Financial Inc. now owns 437,140 shares of the specialty pharmaceutical company’s stock worth $18,841,000 after purchasing an additional 211,950 shares during the period. Institutional investors and hedge funds own 98.22% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.watchlistnews.com/victor-vaughn-sells-55000-shares-of-supernus-pharmaceuticals-inc-supn-stock/1797779.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.